Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

(2010) Timothy L. Lash et al.   ACTA ONCOLOGICA

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

(2010) Bostjan Seruga et al.   BREAST CANCER RESEARCH AND TREATMENT

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer

(2010) Vincent O. Dezentjé et al.   JOURNAL OF CLINICAL ONCOLOGY

No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications

(2009) T. P. Ahern et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues

(2009) David Holzman   JNCI-Journal of the National Cancer Institute

Genotype-guided tamoxifen therapy: time to pause for reflection?

(2009) Timothy L Lash et al.   LANCET ONCOLOGY

Use of Antidepressants for Management of Hot Flashes

(2009) Dana G Carroll et al.   PHARMACOTHERAPY

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram

(2008) T L Lash et al.   BRITISH JOURNAL OF CANCER